Drug Information

Drug (ID: DG01243) and It's Reported Resistant Information

Name	Lobaplatin
Synonyms	131374-93-1; [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+); Lobaplatine; Lobaplatino; Lobaplatinum; Lobaplatin [INN]; Lobaplatine [INN-French]; Lobaplatinum [INN-Latin]; Lobaplatino [INN-Spanish]; NSC619413; NSC 741422; NSC-619413; 2-(Aminomethyl)cyclobutyl]methanamine 2-hydroxypropanoic acid platinum salt; cis-((trans-1,2-Cyclobutandimethylamine)-(s)-2-oxidopropanoato-platinum(II)); cis-(trans-1,2-Cyclobutanebis(methylamine))((S)-lactato-O(sup 1),O(sup 1))platinum; Platinum, (1,2-cyclobutanedimethanamine-N,N')(2-hydroxypropanoato(2-)-O1,O2)-, (SP-4-3-(S),(trans))-; Platinum, (rel-(1R,2R)-1,2-cyclobutanedimethanamine-kappaN,kappaN')((2S)-2-(hydroxy-kappa-O)propanoato(2-)-kappaO)-, (SP-4-3)-; Platinum,2-cyclobutanedimethanamine-N,N') [2-hydroxypropanoato(2-)-O(1),O(2)]-, (SP-4-3) Click to Show/Hide
Indication	In total 1 Indication(s) Breast cancer [ICD-11: 2C60] Approved [1]
Structure
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	C9H18N2O3Pt+2
IsoSMILES	CC(C(=O)[O-])[O-].C1CC(C1CN)CN.[Pt+4]
InChI	1S/C6H14N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-6H,1-4,7-8H2;2H,1H3,(H,5,6);/q;-1;+4/p-1
InChIKey	XSMVECZRZBFTIZ-UHFFFAOYSA-M
PubChem CID	24202037
TTD Drug ID	D0S4QZ

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Osteosarcoma [ICD-11: 2B51]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)			Click to Show/Hide
Key Molecule: Far upstream element-binding protein 1 (FUBP1)				[1]
Molecule Alteration	Expression		Down-regulation	Molecule Info
Sensitive Disease	Osteosarcoma [ICD-11: 2B51.0]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	PC-3 cells	Prostate	Homo sapiens (Human)	CVCL_0035
	SH-1-V6 cells	Esophagus	Homo sapiens (Human)	N.A.
Experiment for Molecule Alteration	Western blotting analysis
Experiment for Drug Resistance	CCK8 assay
Mechanism Description	FUBP1 knockdown conferred lobaplatin sensitivity of osteosarcoma SaOS-2 Cells.

References

Ref 1	Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells .Front Oncol. 2021 Mar 9;11:602712. doi: 10.3389/fonc.2021.602712. eCollection 2021. 10.3389/fonc.2021.602712